INDERAL Drug Patent Profile
✉ Email this page to a colleague
When do Inderal patents expire, and when can generic versions of Inderal launch?
Inderal is a drug marketed by Wyeth Ayerst, Wyeth Pharms, and Ani Pharms. and is included in three NDAs.
The generic ingredient in INDERAL is propranolol hydrochloride. There are twenty-two drug master file entries for this compound. Forty-one suppliers are listed for this compound. Additional details are available on the propranolol hydrochloride profile page.
DrugPatentWatch® Litigation and Generic Entry Outlook for Inderal
A generic version of INDERAL was approved as propranolol hydrochloride by INNOGENIX on October 22nd, 1985.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for INDERAL?
- What are the global sales for INDERAL?
- What is Average Wholesale Price for INDERAL?
Summary for INDERAL
| US Patents: | 0 |
| Applicants: | 3 |
| NDAs: | 3 |
| Raw Ingredient (Bulk) Api Vendors: | 157 |
| Clinical Trials: | 76 |
| Patent Applications: | 3,873 |
| Drug Prices: | Drug price information for INDERAL |
| What excipients (inactive ingredients) are in INDERAL? | INDERAL excipients list |
| DailyMed Link: | INDERAL at DailyMed |
Recent Clinical Trials for INDERAL
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Zealand University Hospital | Phase 2 |
| Rigshospitalet, Denmark | Phase 2 |
| Innovent Biologics (Suzhou) Co. Ltd. | Phase 1 |
US Patents and Regulatory Information for INDERAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Wyeth Ayerst | INDERAL | propranolol hydrochloride | SUSPENSION;ORAL | 019536-001 | Dec 12, 1986 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Wyeth Pharms | INDERAL | propranolol hydrochloride | TABLET;ORAL | 016418-010 | Oct 18, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Wyeth Pharms | INDERAL | propranolol hydrochloride | TABLET;ORAL | 016418-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Ani Pharms | INDERAL LA | propranolol hydrochloride | CAPSULE, EXTENDED RELEASE;ORAL | 018553-004 | Mar 18, 1987 | AB | RX | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | |||
| Wyeth Pharms | INDERAL | propranolol hydrochloride | TABLET;ORAL | 016418-001 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Wyeth Pharms | INDERAL | propranolol hydrochloride | TABLET;ORAL | 016418-003 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Wyeth Pharms | INDERAL | propranolol hydrochloride | TABLET;ORAL | 016418-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
Expired US Patents for INDERAL
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | Patent No. | Patent Expiration |
|---|---|---|---|---|---|---|---|
| Wyeth Ayerst | INDERAL | propranolol hydrochloride | SUSPENSION;ORAL | 019536-001 | Dec 12, 1986 | ⤷ Sign Up | ⤷ Sign Up |
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >Patent No. | >Patent Expiration |
International Patents for INDERAL
See the table below for patents covering INDERAL around the world.
| Country | Patent Number | Title | Estimated Expiration |
|---|---|---|---|
| Canada | 1269619 | FORMULATIONS LIQUIDES DE CHLORHYDRATE DE PROPANOLOL (PROPRANOLOL HYDROCHLORIDE LIQUID FORMULATIONS) | ⤷ Sign Up |
| >Country | >Patent Number | >Title | >Estimated Expiration |
Make Better Decisions: Try a trial or see plans & pricing
Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.
ISSN: 2162-2639
Privacy and Cookies
Terms & Conditions
Site Map
DrugPatentWatch Alternatives
LOE / Major Patent Expirations 2024 - 2025
NCE-1 Patent Challenge Dates 2024 - 2025
Trigger-based marketing for the life sciences
Get DrugPatentWatch Business Intelligence Reports at Amazon.com
DrugChatter - AI-based answers to questions about drugs
RxJam - Digital Marketing for Life Sciences
Friedman, Yali. "DrugPatentWatch" DrugPatentWatch, thinkBiotech, 2024, www.DrugPatentWatch.com.
See Primary Research Papers Citing DrugPatentWatch
Follow DrugPatentWatch:
